Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 128. More products

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Nat-Quetiapine (02439158), Nat-Quetiapine (02439166), Nat-Quetiapine (02439174), Nat-Quetiapine (02439182), Nat-Quetiapine (02439190). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

QUETIAPINE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N05A, N05AH) — coverage varies; not interchangeable

  • Asenapine (Saphris): general benefit
  • Loxapine (Loxapac): general benefit, Not a benefit
  • Olanzapine (Zyprexa Zydis): general benefit, Not a benefit
  • Clozapine (AA-Clozapine Tablet): not a benefit
  • Aripiprazole (Abilify Asimtufii): general benefit
  • Brexpiprazole (Rexulti): general benefit

18 more in the class list below

Act Quetiapine · DIN 02316080 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Quetiapine · DIN 02316080 Manufacturer: Teva Canada Limited; listing date 2008-12-03 Health Canada: Marketed since 2019-12-06 · brand ACT QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 25 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Act Quetiapine: Formulary list price $0.0494/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0494 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80161 · Verify on the e-Formulary ↗ (DIN 02316080)

Source record
DIN 02316080: Act Quetiapine Raw flags: sec3=Y Item: 281608191; group id 506; item number 1321; lccId None; manufacturer id TEV Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0494; ministry $0.0494 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02316080 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80161
Interchangeable products
AG-Quetiapine · DIN 02475979 · $0.0494 Apo-Quetiapine · DIN 02313901 · $0.0494 Apo-Quetiapine Fumarate · DIN 02501635 · $0.0494 Auro-Quetiapine · DIN 02390205 · $0.0494 Bio-Quetiapine · DIN 02447193 · $0.0494 Jamp Quetiapine Fumarate · DIN 02390140 · $0.0494 Jamp-Quetiapine · DIN 02330415 · $0.0494 Mar-Quetiapine · DIN 02399822 · $0.0494 Mint-Quetiapine · DIN 02438003 · $0.0494 NRA-Quetiapine · DIN 02486237 · $0.0494 PMS-Quetiapine · DIN 02296551 · $0.0494 Quetiapine · DIN 02317893 · $0.0494 Quetiapine · DIN 02353164 · $0.0494 Quetiapine Tablets · DIN 02387794 · $0.0494 Ran-Quetiapine · DIN 02397099 · $0.0494 Sandoz Quetiapine · DIN 02313995 · $0.0494 Seroquel · DIN 02236951 · $0.0494 Teva-Quetiapine · DIN 02284235 · $0.0494
Shortage status: resolved shortage (ended 2026-06-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02316080
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Quetiapine · DIN 02390205 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Quetiapine · DIN 02390205 Manufacturer: Auro Pharma Inc.; listing date 2012-12-21 Health Canada: Marketed since 2012-10-18 · brand AURO-QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 25 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Quetiapine: Formulary list price $0.0494/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0494 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87566 · Verify on the e-Formulary ↗ (DIN 02390205)

Source record
DIN 02390205: Auro-Quetiapine Raw flags: sec3=Y Item: 281608191; group id 506; item number 1321; lccId None; manufacturer id AUR Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0494; ministry $0.0494 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02390205 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87566
Interchangeable products
AG-Quetiapine · DIN 02475979 · $0.0494 Act Quetiapine · DIN 02316080 · $0.0494 Apo-Quetiapine · DIN 02313901 · $0.0494 Apo-Quetiapine Fumarate · DIN 02501635 · $0.0494 Bio-Quetiapine · DIN 02447193 · $0.0494 Jamp Quetiapine Fumarate · DIN 02390140 · $0.0494 Jamp-Quetiapine · DIN 02330415 · $0.0494 Mar-Quetiapine · DIN 02399822 · $0.0494 Mint-Quetiapine · DIN 02438003 · $0.0494 NRA-Quetiapine · DIN 02486237 · $0.0494 PMS-Quetiapine · DIN 02296551 · $0.0494 Quetiapine · DIN 02317893 · $0.0494 Quetiapine · DIN 02353164 · $0.0494 Quetiapine Tablets · DIN 02387794 · $0.0494 Ran-Quetiapine · DIN 02397099 · $0.0494 Sandoz Quetiapine · DIN 02313995 · $0.0494 Seroquel · DIN 02236951 · $0.0494 Teva-Quetiapine · DIN 02284235 · $0.0494
Shortage status: resolved shortage (ended 2024-11-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02390205
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bio-Quetiapine · DIN 02447193 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Bio-Quetiapine · DIN 02447193 Manufacturer: Biomed Pharma; listing date 2016-02-25 Health Canada: Marketed since 2016-09-07 · brand BIO-QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet (immediate-release) · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 25 MG · company Biomed pharma · schedule Prescription
Check this DIN again · Health Canada product record

Bio-Quetiapine: Formulary list price $0.0494/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0494 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93276 · Verify on the e-Formulary ↗ (DIN 02447193)

Source record
DIN 02447193: Bio-Quetiapine Raw flags: sec3=Y Item: 281608191; group id 506; item number 1321; lccId None; manufacturer id BMP Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0494; ministry $0.0494 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02447193 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93276
Interchangeable products
AG-Quetiapine · DIN 02475979 · $0.0494 Act Quetiapine · DIN 02316080 · $0.0494 Apo-Quetiapine · DIN 02313901 · $0.0494 Apo-Quetiapine Fumarate · DIN 02501635 · $0.0494 Auro-Quetiapine · DIN 02390205 · $0.0494 Jamp Quetiapine Fumarate · DIN 02390140 · $0.0494 Jamp-Quetiapine · DIN 02330415 · $0.0494 Mar-Quetiapine · DIN 02399822 · $0.0494 Mint-Quetiapine · DIN 02438003 · $0.0494 NRA-Quetiapine · DIN 02486237 · $0.0494 PMS-Quetiapine · DIN 02296551 · $0.0494 Quetiapine · DIN 02317893 · $0.0494 Quetiapine · DIN 02353164 · $0.0494 Quetiapine Tablets · DIN 02387794 · $0.0494 Ran-Quetiapine · DIN 02397099 · $0.0494 Sandoz Quetiapine · DIN 02313995 · $0.0494 Seroquel · DIN 02236951 · $0.0494 Teva-Quetiapine · DIN 02284235 · $0.0494
Shortage status: active shortage (reported 2024-05-08, last updated 2024-12-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02447193
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Quetiapine Fumarate · DIN 02390140 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Quetiapine Fumarate · DIN 02390140 Manufacturer: Jamp Pharma Corporation; listing date 2021-12-17 Health Canada: Marketed since 2021-11-03 · brand JAMP QUETIAPINE FUMARATE · ATC N05AH04 QUETIAPINE · form Tablet (immediate-release) · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 25 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Quetiapine Fumarate: Formulary list price $0.0494/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0494 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87560 · Verify on the e-Formulary ↗ (DIN 02390140)

Source record
DIN 02390140: Jamp Quetiapine Fumarate Raw flags: sec3=Y Item: 281608191; group id 506; item number 1321; lccId None; manufacturer id JPC Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0494; ministry $0.0494 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02390140 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87560
Interchangeable products
AG-Quetiapine · DIN 02475979 · $0.0494 Act Quetiapine · DIN 02316080 · $0.0494 Apo-Quetiapine · DIN 02313901 · $0.0494 Apo-Quetiapine Fumarate · DIN 02501635 · $0.0494 Auro-Quetiapine · DIN 02390205 · $0.0494 Bio-Quetiapine · DIN 02447193 · $0.0494 Jamp-Quetiapine · DIN 02330415 · $0.0494 Mar-Quetiapine · DIN 02399822 · $0.0494 Mint-Quetiapine · DIN 02438003 · $0.0494 NRA-Quetiapine · DIN 02486237 · $0.0494 PMS-Quetiapine · DIN 02296551 · $0.0494 Quetiapine · DIN 02317893 · $0.0494 Quetiapine · DIN 02353164 · $0.0494 Quetiapine Tablets · DIN 02387794 · $0.0494 Ran-Quetiapine · DIN 02397099 · $0.0494 Sandoz Quetiapine · DIN 02313995 · $0.0494 Seroquel · DIN 02236951 · $0.0494 Teva-Quetiapine · DIN 02284235 · $0.0494
Shortage status: resolved shortage (ended 2023-08-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02390140
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Quetiapine · DIN 02438003 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Quetiapine · DIN 02438003 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2016-04-01 Health Canada: Marketed since 2015-03-19 · brand MINT-QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 25 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Quetiapine: Formulary list price $0.0494/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0494 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92237 · Verify on the e-Formulary ↗ (DIN 02438003)

Source record
DIN 02438003: Mint-Quetiapine Raw flags: sec3=Y Item: 281608191; group id 506; item number 1321; lccId None; manufacturer id MIN Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0494; ministry $0.0494 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02438003 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92237
Interchangeable products
AG-Quetiapine · DIN 02475979 · $0.0494 Act Quetiapine · DIN 02316080 · $0.0494 Apo-Quetiapine · DIN 02313901 · $0.0494 Apo-Quetiapine Fumarate · DIN 02501635 · $0.0494 Auro-Quetiapine · DIN 02390205 · $0.0494 Bio-Quetiapine · DIN 02447193 · $0.0494 Jamp Quetiapine Fumarate · DIN 02390140 · $0.0494 Jamp-Quetiapine · DIN 02330415 · $0.0494 Mar-Quetiapine · DIN 02399822 · $0.0494 NRA-Quetiapine · DIN 02486237 · $0.0494 PMS-Quetiapine · DIN 02296551 · $0.0494 Quetiapine · DIN 02317893 · $0.0494 Quetiapine · DIN 02353164 · $0.0494 Quetiapine Tablets · DIN 02387794 · $0.0494 Ran-Quetiapine · DIN 02397099 · $0.0494 Sandoz Quetiapine · DIN 02313995 · $0.0494 Seroquel · DIN 02236951 · $0.0494 Teva-Quetiapine · DIN 02284235 · $0.0494
Shortage status: resolved shortage (ended 2018-05-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02438003
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Quetiapine · DIN 02486237 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Quetiapine · DIN 02486237 Manufacturer: Nora Pharma; listing date 2020-10-30 Health Canada: Marketed since 2022-11-09 · brand NRA-QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet (immediate-release) · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 25 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Quetiapine: Formulary list price $0.0494/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0494 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97646 · Verify on the e-Formulary ↗ (DIN 02486237)

Source record
DIN 02486237: NRA-Quetiapine Raw flags: sec3=Y Item: 281608191; group id 506; item number 1321; lccId None; manufacturer id NRA Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0494; ministry $0.0494 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02486237 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97646
Interchangeable products
AG-Quetiapine · DIN 02475979 · $0.0494 Act Quetiapine · DIN 02316080 · $0.0494 Apo-Quetiapine · DIN 02313901 · $0.0494 Apo-Quetiapine Fumarate · DIN 02501635 · $0.0494 Auro-Quetiapine · DIN 02390205 · $0.0494 Bio-Quetiapine · DIN 02447193 · $0.0494 Jamp Quetiapine Fumarate · DIN 02390140 · $0.0494 Jamp-Quetiapine · DIN 02330415 · $0.0494 Mar-Quetiapine · DIN 02399822 · $0.0494 Mint-Quetiapine · DIN 02438003 · $0.0494 PMS-Quetiapine · DIN 02296551 · $0.0494 Quetiapine · DIN 02317893 · $0.0494 Quetiapine · DIN 02353164 · $0.0494 Quetiapine Tablets · DIN 02387794 · $0.0494 Ran-Quetiapine · DIN 02397099 · $0.0494 Sandoz Quetiapine · DIN 02313995 · $0.0494 Seroquel · DIN 02236951 · $0.0494 Teva-Quetiapine · DIN 02284235 · $0.0494
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02486237
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Quetiapine · DIN 02296551 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Quetiapine · DIN 02296551 Manufacturer: Pharmascience Inc.; listing date 2008-12-03 Health Canada: Marketed since 2008-09-04 · brand PMS-QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 25 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Quetiapine: Formulary list price $0.0494/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0494 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78188 · Verify on the e-Formulary ↗ (DIN 02296551)

Source record
DIN 02296551: PMS-Quetiapine Raw flags: sec3=Y Item: 281608191; group id 506; item number 1321; lccId None; manufacturer id PMS Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0494; ministry $0.0494 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02296551 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78188
Interchangeable products
AG-Quetiapine · DIN 02475979 · $0.0494 Act Quetiapine · DIN 02316080 · $0.0494 Apo-Quetiapine · DIN 02313901 · $0.0494 Apo-Quetiapine Fumarate · DIN 02501635 · $0.0494 Auro-Quetiapine · DIN 02390205 · $0.0494 Bio-Quetiapine · DIN 02447193 · $0.0494 Jamp Quetiapine Fumarate · DIN 02390140 · $0.0494 Jamp-Quetiapine · DIN 02330415 · $0.0494 Mar-Quetiapine · DIN 02399822 · $0.0494 Mint-Quetiapine · DIN 02438003 · $0.0494 NRA-Quetiapine · DIN 02486237 · $0.0494 Quetiapine · DIN 02317893 · $0.0494 Quetiapine · DIN 02353164 · $0.0494 Quetiapine Tablets · DIN 02387794 · $0.0494 Ran-Quetiapine · DIN 02397099 · $0.0494 Sandoz Quetiapine · DIN 02313995 · $0.0494 Seroquel · DIN 02236951 · $0.0494 Teva-Quetiapine · DIN 02284235 · $0.0494
Shortage status: resolved shortage (ended 2018-12-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02296551
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Quetiapine · DIN 02317893 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Quetiapine · DIN 02317893 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-06-14 Health Canada: Marketed since 2016-08-12 · brand QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Quetiapine: Formulary list price $0.0494/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0494 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80341 · Verify on the e-Formulary ↗ (DIN 02317893)

Source record
DIN 02317893: Quetiapine Raw flags: sec3=Y Item: 281608191; group id 506; item number 1321; lccId None; manufacturer id SIV Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0494; ministry $0.0494 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02317893 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80341
Interchangeable products
AG-Quetiapine · DIN 02475979 · $0.0494 Act Quetiapine · DIN 02316080 · $0.0494 Apo-Quetiapine · DIN 02313901 · $0.0494 Apo-Quetiapine Fumarate · DIN 02501635 · $0.0494 Auro-Quetiapine · DIN 02390205 · $0.0494 Bio-Quetiapine · DIN 02447193 · $0.0494 Jamp Quetiapine Fumarate · DIN 02390140 · $0.0494 Jamp-Quetiapine · DIN 02330415 · $0.0494 Mar-Quetiapine · DIN 02399822 · $0.0494 Mint-Quetiapine · DIN 02438003 · $0.0494 NRA-Quetiapine · DIN 02486237 · $0.0494 PMS-Quetiapine · DIN 02296551 · $0.0494 Quetiapine · DIN 02353164 · $0.0494 Quetiapine Tablets · DIN 02387794 · $0.0494 Ran-Quetiapine · DIN 02397099 · $0.0494 Sandoz Quetiapine · DIN 02313995 · $0.0494 Seroquel · DIN 02236951 · $0.0494 Teva-Quetiapine · DIN 02284235 · $0.0494
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02317893
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Quetiapine · DIN 02353164 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Quetiapine · DIN 02353164 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2010-07-26 · brand QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 25 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Quetiapine: Formulary list price $0.0494/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0494 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83838 · Verify on the e-Formulary ↗ (DIN 02353164)

Source record
DIN 02353164: Quetiapine Raw flags: sec3=Y Item: 281608191; group id 506; item number 1321; lccId None; manufacturer id SAI Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0494; ministry $0.0494 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02353164 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83838
Interchangeable products
AG-Quetiapine · DIN 02475979 · $0.0494 Act Quetiapine · DIN 02316080 · $0.0494 Apo-Quetiapine · DIN 02313901 · $0.0494 Apo-Quetiapine Fumarate · DIN 02501635 · $0.0494 Auro-Quetiapine · DIN 02390205 · $0.0494 Bio-Quetiapine · DIN 02447193 · $0.0494 Jamp Quetiapine Fumarate · DIN 02390140 · $0.0494 Jamp-Quetiapine · DIN 02330415 · $0.0494 Mar-Quetiapine · DIN 02399822 · $0.0494 Mint-Quetiapine · DIN 02438003 · $0.0494 NRA-Quetiapine · DIN 02486237 · $0.0494 PMS-Quetiapine · DIN 02296551 · $0.0494 Quetiapine · DIN 02317893 · $0.0494 Quetiapine Tablets · DIN 02387794 · $0.0494 Ran-Quetiapine · DIN 02397099 · $0.0494 Sandoz Quetiapine · DIN 02313995 · $0.0494 Seroquel · DIN 02236951 · $0.0494 Teva-Quetiapine · DIN 02284235 · $0.0494
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02353164
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Quetiapine Tablets · DIN 02387794 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Quetiapine Tablets · DIN 02387794 Manufacturer: Accord Healthcare Inc.; listing date 2012-09-28 Health Canada: Marketed since 2024-04-03 · brand ACH-QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet (immediate-release) · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 25 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Quetiapine Tablets: Formulary list price $0.0494/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0494 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87337 · Verify on the e-Formulary ↗ (DIN 02387794)

Source record
DIN 02387794: Quetiapine Tablets Raw flags: sec3=Y Item: 281608191; group id 506; item number 1321; lccId None; manufacturer id ACH Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0494; ministry $0.0494 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02387794 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87337
Interchangeable products
AG-Quetiapine · DIN 02475979 · $0.0494 Act Quetiapine · DIN 02316080 · $0.0494 Apo-Quetiapine · DIN 02313901 · $0.0494 Apo-Quetiapine Fumarate · DIN 02501635 · $0.0494 Auro-Quetiapine · DIN 02390205 · $0.0494 Bio-Quetiapine · DIN 02447193 · $0.0494 Jamp Quetiapine Fumarate · DIN 02390140 · $0.0494 Jamp-Quetiapine · DIN 02330415 · $0.0494 Mar-Quetiapine · DIN 02399822 · $0.0494 Mint-Quetiapine · DIN 02438003 · $0.0494 NRA-Quetiapine · DIN 02486237 · $0.0494 PMS-Quetiapine · DIN 02296551 · $0.0494 Quetiapine · DIN 02317893 · $0.0494 Quetiapine · DIN 02353164 · $0.0494 Ran-Quetiapine · DIN 02397099 · $0.0494 Sandoz Quetiapine · DIN 02313995 · $0.0494 Seroquel · DIN 02236951 · $0.0494 Teva-Quetiapine · DIN 02284235 · $0.0494
Shortage status: resolved shortage (ended 2026-07-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02387794
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Seroquel · DIN 02236951 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists SEROQUEL (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Seroquel · DIN 02236951 Manufacturer: AstraZeneca; listing date 1998-12-31 Health Canada: Marketed since 2025-11-28 · brand SEROQUEL · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 25 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.0494 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60245 · Verify on the e-Formulary ↗ (DIN 02236951)

Source record
DIN 02236951: Seroquel Raw flags: sec3=Y Item: 281608191; group id 506; item number 1321; lccId None; manufacturer id AZC Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.5491; ministry $0.0494 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02236951 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60245
Interchangeable products
AG-Quetiapine · DIN 02475979 · $0.0494 Act Quetiapine · DIN 02316080 · $0.0494 Apo-Quetiapine · DIN 02313901 · $0.0494 Apo-Quetiapine Fumarate · DIN 02501635 · $0.0494 Auro-Quetiapine · DIN 02390205 · $0.0494 Bio-Quetiapine · DIN 02447193 · $0.0494 Jamp Quetiapine Fumarate · DIN 02390140 · $0.0494 Jamp-Quetiapine · DIN 02330415 · $0.0494 Mar-Quetiapine · DIN 02399822 · $0.0494 Mint-Quetiapine · DIN 02438003 · $0.0494 NRA-Quetiapine · DIN 02486237 · $0.0494 PMS-Quetiapine · DIN 02296551 · $0.0494 Quetiapine · DIN 02317893 · $0.0494 Quetiapine · DIN 02353164 · $0.0494 Quetiapine Tablets · DIN 02387794 · $0.0494 Ran-Quetiapine · DIN 02397099 · $0.0494 Sandoz Quetiapine · DIN 02313995 · $0.0494 Teva-Quetiapine · DIN 02284235 · $0.0494
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02236951
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ach-Quetiapine Fumarate XR · DIN 02450860 · 50mg · extended release tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Quetiapine Fumarate XR · DIN 02450860 Manufacturer: Accord Healthcare Inc.; listing date 2021-03-29 Health Canada: Marketed since 2020-10-21 · brand ACH-QUETIAPINE FUMARATE XR · ATC N05AH04 QUETIAPINE · form Tablet (extended-release) · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 50 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Ach-Quetiapine Fumarate XR: Formulary list price $0.2501/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2501 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93699 · Verify on the e-Formulary ↗ (DIN 02450860)

Source record
DIN 02450860: Ach-Quetiapine Fumarate XR Raw flags: sec3=Y Item: 281608235; group id 506; item number 1316; lccId None; manufacturer id ACH Source form: ER Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2501; ministry $0.2501 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02450860 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93699
Interchangeable products
Apo-Quetiapine XR · DIN 02457229 · $0.2501 M-Quetiapine Fumarate XR · DIN 02527928 · $0.2501 Mint-Quetiapine XR · DIN 02522187 · $0.2501 NRA-Quetiapine XR · DIN 02510677 · $0.2501 Quetiapine Fumarate XR · DIN 02516616 · $0.2501 Quetiapine XR · DIN 02417359 · $0.2501 Quetiapine XR · DIN 02519607 · $0.2501 Sandoz Quetiapine XRT · DIN 02407671 · $0.2501 Seroquel XR · DIN 02300184 · $0.2501 Teva-Quetiapine XR · DIN 02395444 · $0.2501
Shortage status: active shortage (reported 2023-12-15, last updated 2024-01-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02450860
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Quetiapine XR · DIN 02417359 · 50mg · extended release tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Quetiapine XR · DIN 02417359 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2025-06-11 · brand QUETIAPINE XR · ATC N05AH04 QUETIAPINE · form Tablet (extended-release) · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 50 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Quetiapine XR: Formulary list price $0.2501/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2501 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90198 · Verify on the e-Formulary ↗ (DIN 02417359)

Source record
DIN 02417359: Quetiapine XR Raw flags: sec3=Y Item: 281608235; group id 506; item number 1316; lccId None; manufacturer id SIV Source form: ER Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2501; ministry $0.2501 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02417359 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90198
Interchangeable products
Ach-Quetiapine Fumarate XR · DIN 02450860 · $0.2501 Apo-Quetiapine XR · DIN 02457229 · $0.2501 M-Quetiapine Fumarate XR · DIN 02527928 · $0.2501 Mint-Quetiapine XR · DIN 02522187 · $0.2501 NRA-Quetiapine XR · DIN 02510677 · $0.2501 Quetiapine Fumarate XR · DIN 02516616 · $0.2501 Quetiapine XR · DIN 02519607 · $0.2501 Sandoz Quetiapine XRT · DIN 02407671 · $0.2501 Seroquel XR · DIN 02300184 · $0.2501 Teva-Quetiapine XR · DIN 02395444 · $0.2501
Shortage status: resolved shortage (ended 2025-06-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02417359
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Quetiapine XRT · DIN 02407671 · 50mg · extended release tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Quetiapine XRT · DIN 02407671 Manufacturer: Sandoz Canada Inc.; listing date 2013-10-31 Health Canada: Marketed since 2017-11-07 · brand SANDOZ QUETIAPINE XRT · ATC N05AH04 QUETIAPINE · form Tablet (extended-release) · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 50 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Quetiapine XRT: Formulary list price $0.2501/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2501 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89240 · Verify on the e-Formulary ↗ (DIN 02407671)

Source record
DIN 02407671: Sandoz Quetiapine XRT Raw flags: sec3=Y Item: 281608235; group id 506; item number 1316; lccId None; manufacturer id SDZ Source form: ER Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2501; ministry $0.2501 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02407671 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89240
Interchangeable products
Ach-Quetiapine Fumarate XR · DIN 02450860 · $0.2501 Apo-Quetiapine XR · DIN 02457229 · $0.2501 M-Quetiapine Fumarate XR · DIN 02527928 · $0.2501 Mint-Quetiapine XR · DIN 02522187 · $0.2501 NRA-Quetiapine XR · DIN 02510677 · $0.2501 Quetiapine Fumarate XR · DIN 02516616 · $0.2501 Quetiapine XR · DIN 02417359 · $0.2501 Quetiapine XR · DIN 02519607 · $0.2501 Seroquel XR · DIN 02300184 · $0.2501 Teva-Quetiapine XR · DIN 02395444 · $0.2501
Shortage status: resolved shortage (ended 2017-10-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02407671
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Seroquel XR · DIN 02300184 · 50mg · extended release tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Seroquel XR (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists SEROQUEL XR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)
1 brand, same coverage
Seroquel XR · DIN 02300184 Manufacturer: AstraZeneca; listing date 2008-06-27 Health Canada: Marketed since 2025-11-05 · brand SEROQUEL XR · ATC N05AH04 QUETIAPINE · form Tablet (extended-release) · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 50 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2501 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78550 · Verify on the e-Formulary ↗ (DIN 02300184)

Source record
DIN 02300184: Seroquel XR Raw flags: sec3=Y Item: 281608235; group id 506; item number 1316; lccId None; manufacturer id AZC Source form: ER Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.1523; ministry $0.2501 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02300184 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78550
Interchangeable products
Ach-Quetiapine Fumarate XR · DIN 02450860 · $0.2501 Apo-Quetiapine XR · DIN 02457229 · $0.2501 M-Quetiapine Fumarate XR · DIN 02527928 · $0.2501 Mint-Quetiapine XR · DIN 02522187 · $0.2501 NRA-Quetiapine XR · DIN 02510677 · $0.2501 Quetiapine Fumarate XR · DIN 02516616 · $0.2501 Quetiapine XR · DIN 02417359 · $0.2501 Quetiapine XR · DIN 02519607 · $0.2501 Sandoz Quetiapine XRT · DIN 02407671 · $0.2501 Teva-Quetiapine XR · DIN 02395444 · $0.2501
Shortage status: resolved shortage (ended 2025-10-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02300184
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Quetiapine XR · DIN 02395444 · 50mg · extended release tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Quetiapine XR · DIN 02395444 Manufacturer: Teva Canada Limited; listing date 2013-04-30 Health Canada: Marketed since 2013-03-08 · brand TEVA-QUETIAPINE XR · ATC N05AH04 QUETIAPINE · form Tablet (extended-release) · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 50 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Quetiapine XR: Formulary list price $0.2501/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2501 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88053 · Verify on the e-Formulary ↗ (DIN 02395444)

Source record
DIN 02395444: Teva-Quetiapine XR Raw flags: sec3=Y Item: 281608235; group id 506; item number 1316; lccId None; manufacturer id TEV Source form: ER Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.2501; ministry $0.2501 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02395444 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88053
Interchangeable products
Ach-Quetiapine Fumarate XR · DIN 02450860 · $0.2501 Apo-Quetiapine XR · DIN 02457229 · $0.2501 M-Quetiapine Fumarate XR · DIN 02527928 · $0.2501 Mint-Quetiapine XR · DIN 02522187 · $0.2501 NRA-Quetiapine XR · DIN 02510677 · $0.2501 Quetiapine Fumarate XR · DIN 02516616 · $0.2501 Quetiapine XR · DIN 02417359 · $0.2501 Quetiapine XR · DIN 02519607 · $0.2501 Sandoz Quetiapine XRT · DIN 02407671 · $0.2501 Seroquel XR · DIN 02300184 · $0.2501
Shortage status: resolved shortage (ended 2026-08-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02395444
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Act Quetiapine · DIN 02316099 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Quetiapine · DIN 02316099 Manufacturer: Teva Canada Limited; listing date 2008-12-03 Health Canada: Marketed since 2019-12-06 · brand ACT QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 100 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Act Quetiapine: Formulary list price $0.1318/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1318 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80162 · Verify on the e-Formulary ↗ (DIN 02316099)

Source record
DIN 02316099: Act Quetiapine Raw flags: sec3=Y Item: 281608192; group id 506; item number 1322; lccId None; manufacturer id TEV Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.1318; ministry $0.1318 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02316099 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80162
Interchangeable products
Apo-Quetiapine · DIN 02313928 · $0.1318 Apo-Quetiapine Fumarate · DIN 02501643 · $0.1318 Auro-Quetiapine · DIN 02390213 · $0.1318 Bio-Quetiapine · DIN 02447207 · $0.1318 Jamp Quetiapine Fumarate · DIN 02390159 · $0.1318 Jamp-Quetiapine · DIN 02330423 · $0.1318 Mar-Quetiapine · DIN 02399830 · $0.1318 Mint-Quetiapine · DIN 02438011 · $0.1318 PMS-Quetiapine · DIN 02296578 · $0.1318 Quetiapine · DIN 02317907 · $0.1318 Quetiapine · DIN 02353172 · $0.1318 Quetiapine Tablets · DIN 02387808 · $0.1318 Ran-Quetiapine · DIN 02397102 · $0.1318 Sandoz Quetiapine · DIN 02314002 · $0.1318 Seroquel · DIN 02236952 · $0.1318 Teva-Quetiapine · DIN 02284243 · $0.1318
Shortage status: resolved shortage (ended 2026-05-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02316099
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Quetiapine Fumarate · DIN 02501643 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Quetiapine Fumarate · DIN 02501643 Manufacturer: Apotex Inc.; listing date 2021-08-31 Health Canada: Marketed since 2021-07-28 · brand APO-QUETIAPINE FUMARATE · ATC N05AH04 QUETIAPINE · form Tablet (immediate-release) · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 100 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Quetiapine Fumarate: Formulary list price $0.1318/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1318 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99126 · Verify on the e-Formulary ↗ (DIN 02501643)

Source record
DIN 02501643: Apo-Quetiapine Fumarate Raw flags: sec3=Y Item: 281608192; group id 506; item number 1322; lccId None; manufacturer id APX Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.1318; ministry $0.1318 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02501643 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99126
Interchangeable products
Act Quetiapine · DIN 02316099 · $0.1318 Apo-Quetiapine · DIN 02313928 · $0.1318 Auro-Quetiapine · DIN 02390213 · $0.1318 Bio-Quetiapine · DIN 02447207 · $0.1318 Jamp Quetiapine Fumarate · DIN 02390159 · $0.1318 Jamp-Quetiapine · DIN 02330423 · $0.1318 Mar-Quetiapine · DIN 02399830 · $0.1318 Mint-Quetiapine · DIN 02438011 · $0.1318 PMS-Quetiapine · DIN 02296578 · $0.1318 Quetiapine · DIN 02317907 · $0.1318 Quetiapine · DIN 02353172 · $0.1318 Quetiapine Tablets · DIN 02387808 · $0.1318 Ran-Quetiapine · DIN 02397102 · $0.1318 Sandoz Quetiapine · DIN 02314002 · $0.1318 Seroquel · DIN 02236952 · $0.1318 Teva-Quetiapine · DIN 02284243 · $0.1318
Shortage status: active shortage (reported not recorded, last updated 2024-09-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02501643
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Quetiapine · DIN 02390213 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Quetiapine · DIN 02390213 Manufacturer: Auro Pharma Inc.; listing date 2012-12-21 Health Canada: Marketed since 2012-10-18 · brand AURO-QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 100 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Quetiapine: Formulary list price $0.1318/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1318 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87567 · Verify on the e-Formulary ↗ (DIN 02390213)

Source record
DIN 02390213: Auro-Quetiapine Raw flags: sec3=Y Item: 281608192; group id 506; item number 1322; lccId None; manufacturer id AUR Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.1318; ministry $0.1318 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02390213 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87567
Interchangeable products
Act Quetiapine · DIN 02316099 · $0.1318 Apo-Quetiapine · DIN 02313928 · $0.1318 Apo-Quetiapine Fumarate · DIN 02501643 · $0.1318 Bio-Quetiapine · DIN 02447207 · $0.1318 Jamp Quetiapine Fumarate · DIN 02390159 · $0.1318 Jamp-Quetiapine · DIN 02330423 · $0.1318 Mar-Quetiapine · DIN 02399830 · $0.1318 Mint-Quetiapine · DIN 02438011 · $0.1318 PMS-Quetiapine · DIN 02296578 · $0.1318 Quetiapine · DIN 02317907 · $0.1318 Quetiapine · DIN 02353172 · $0.1318 Quetiapine Tablets · DIN 02387808 · $0.1318 Ran-Quetiapine · DIN 02397102 · $0.1318 Sandoz Quetiapine · DIN 02314002 · $0.1318 Seroquel · DIN 02236952 · $0.1318 Teva-Quetiapine · DIN 02284243 · $0.1318
Shortage status: resolved shortage (ended 2024-07-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02390213
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Quetiapine Fumarate · DIN 02390159 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Quetiapine Fumarate · DIN 02390159 Manufacturer: Jamp Pharma Corporation; listing date 2021-12-17 Health Canada: Marketed since 2021-11-03 · brand JAMP QUETIAPINE FUMARATE · ATC N05AH04 QUETIAPINE · form Tablet (immediate-release) · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 100 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Quetiapine Fumarate: Formulary list price $0.1318/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1318 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87561 · Verify on the e-Formulary ↗ (DIN 02390159)

Source record
DIN 02390159: Jamp Quetiapine Fumarate Raw flags: sec3=Y Item: 281608192; group id 506; item number 1322; lccId None; manufacturer id JPC Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.1318; ministry $0.1318 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02390159 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87561
Interchangeable products
Act Quetiapine · DIN 02316099 · $0.1318 Apo-Quetiapine · DIN 02313928 · $0.1318 Apo-Quetiapine Fumarate · DIN 02501643 · $0.1318 Auro-Quetiapine · DIN 02390213 · $0.1318 Bio-Quetiapine · DIN 02447207 · $0.1318 Jamp-Quetiapine · DIN 02330423 · $0.1318 Mar-Quetiapine · DIN 02399830 · $0.1318 Mint-Quetiapine · DIN 02438011 · $0.1318 PMS-Quetiapine · DIN 02296578 · $0.1318 Quetiapine · DIN 02317907 · $0.1318 Quetiapine · DIN 02353172 · $0.1318 Quetiapine Tablets · DIN 02387808 · $0.1318 Ran-Quetiapine · DIN 02397102 · $0.1318 Sandoz Quetiapine · DIN 02314002 · $0.1318 Seroquel · DIN 02236952 · $0.1318 Teva-Quetiapine · DIN 02284243 · $0.1318
Shortage status: resolved shortage (ended 2025-04-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02390159
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Quetiapine · DIN 02438011 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Quetiapine · DIN 02438011 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2016-04-01 Health Canada: Marketed since 2015-03-19 · brand MINT-QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 100 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Quetiapine: Formulary list price $0.1318/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1318 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92238 · Verify on the e-Formulary ↗ (DIN 02438011)

Source record
DIN 02438011: Mint-Quetiapine Raw flags: sec3=Y Item: 281608192; group id 506; item number 1322; lccId None; manufacturer id MIN Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.1318; ministry $0.1318 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02438011 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92238
Interchangeable products
Act Quetiapine · DIN 02316099 · $0.1318 Apo-Quetiapine · DIN 02313928 · $0.1318 Apo-Quetiapine Fumarate · DIN 02501643 · $0.1318 Auro-Quetiapine · DIN 02390213 · $0.1318 Bio-Quetiapine · DIN 02447207 · $0.1318 Jamp Quetiapine Fumarate · DIN 02390159 · $0.1318 Jamp-Quetiapine · DIN 02330423 · $0.1318 Mar-Quetiapine · DIN 02399830 · $0.1318 PMS-Quetiapine · DIN 02296578 · $0.1318 Quetiapine · DIN 02317907 · $0.1318 Quetiapine · DIN 02353172 · $0.1318 Quetiapine Tablets · DIN 02387808 · $0.1318 Ran-Quetiapine · DIN 02397102 · $0.1318 Sandoz Quetiapine · DIN 02314002 · $0.1318 Seroquel · DIN 02236952 · $0.1318 Teva-Quetiapine · DIN 02284243 · $0.1318
Shortage status: resolved shortage (ended 2018-04-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02438011
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Quetiapine · DIN 02296578 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Quetiapine · DIN 02296578 Manufacturer: Pharmascience Inc.; listing date 2008-12-03 Health Canada: Marketed since 2008-09-04 · brand PMS-QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 100 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Quetiapine: Formulary list price $0.1318/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1318 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78189 · Verify on the e-Formulary ↗ (DIN 02296578)

Source record
DIN 02296578: PMS-Quetiapine Raw flags: sec3=Y Item: 281608192; group id 506; item number 1322; lccId None; manufacturer id PMS Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.1318; ministry $0.1318 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02296578 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78189
Interchangeable products
Act Quetiapine · DIN 02316099 · $0.1318 Apo-Quetiapine · DIN 02313928 · $0.1318 Apo-Quetiapine Fumarate · DIN 02501643 · $0.1318 Auro-Quetiapine · DIN 02390213 · $0.1318 Bio-Quetiapine · DIN 02447207 · $0.1318 Jamp Quetiapine Fumarate · DIN 02390159 · $0.1318 Jamp-Quetiapine · DIN 02330423 · $0.1318 Mar-Quetiapine · DIN 02399830 · $0.1318 Mint-Quetiapine · DIN 02438011 · $0.1318 Quetiapine · DIN 02317907 · $0.1318 Quetiapine · DIN 02353172 · $0.1318 Quetiapine Tablets · DIN 02387808 · $0.1318 Ran-Quetiapine · DIN 02397102 · $0.1318 Sandoz Quetiapine · DIN 02314002 · $0.1318 Seroquel · DIN 02236952 · $0.1318 Teva-Quetiapine · DIN 02284243 · $0.1318
Shortage status: resolved shortage (ended 2017-11-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02296578
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Quetiapine · DIN 02317907 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Quetiapine · DIN 02317907 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-06-14 Health Canada: Marketed since 2016-08-12 · brand QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Quetiapine: Formulary list price $0.1318/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1318 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80342 · Verify on the e-Formulary ↗ (DIN 02317907)

Source record
DIN 02317907: Quetiapine Raw flags: sec3=Y Item: 281608192; group id 506; item number 1322; lccId None; manufacturer id SIV Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.1318; ministry $0.1318 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02317907 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80342
Interchangeable products
Act Quetiapine · DIN 02316099 · $0.1318 Apo-Quetiapine · DIN 02313928 · $0.1318 Apo-Quetiapine Fumarate · DIN 02501643 · $0.1318 Auro-Quetiapine · DIN 02390213 · $0.1318 Bio-Quetiapine · DIN 02447207 · $0.1318 Jamp Quetiapine Fumarate · DIN 02390159 · $0.1318 Jamp-Quetiapine · DIN 02330423 · $0.1318 Mar-Quetiapine · DIN 02399830 · $0.1318 Mint-Quetiapine · DIN 02438011 · $0.1318 PMS-Quetiapine · DIN 02296578 · $0.1318 Quetiapine · DIN 02353172 · $0.1318 Quetiapine Tablets · DIN 02387808 · $0.1318 Ran-Quetiapine · DIN 02397102 · $0.1318 Sandoz Quetiapine · DIN 02314002 · $0.1318 Seroquel · DIN 02236952 · $0.1318 Teva-Quetiapine · DIN 02284243 · $0.1318
Shortage status: resolved shortage (ended 2023-06-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02317907
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Quetiapine · DIN 02353172 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Quetiapine · DIN 02353172 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2010-07-26 · brand QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 100 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Quetiapine: Formulary list price $0.1318/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1318 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83839 · Verify on the e-Formulary ↗ (DIN 02353172)

Source record
DIN 02353172: Quetiapine Raw flags: sec3=Y Item: 281608192; group id 506; item number 1322; lccId None; manufacturer id SAI Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.1318; ministry $0.1318 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02353172 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83839
Interchangeable products
Act Quetiapine · DIN 02316099 · $0.1318 Apo-Quetiapine · DIN 02313928 · $0.1318 Apo-Quetiapine Fumarate · DIN 02501643 · $0.1318 Auro-Quetiapine · DIN 02390213 · $0.1318 Bio-Quetiapine · DIN 02447207 · $0.1318 Jamp Quetiapine Fumarate · DIN 02390159 · $0.1318 Jamp-Quetiapine · DIN 02330423 · $0.1318 Mar-Quetiapine · DIN 02399830 · $0.1318 Mint-Quetiapine · DIN 02438011 · $0.1318 PMS-Quetiapine · DIN 02296578 · $0.1318 Quetiapine · DIN 02317907 · $0.1318 Quetiapine Tablets · DIN 02387808 · $0.1318 Ran-Quetiapine · DIN 02397102 · $0.1318 Sandoz Quetiapine · DIN 02314002 · $0.1318 Seroquel · DIN 02236952 · $0.1318 Teva-Quetiapine · DIN 02284243 · $0.1318
Shortage status: resolved shortage (ended 2019-02-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02353172
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab

OLANZAPINE

· 116 products · General benefit (99), Off-Formulary Interchangeable, not an ODB benefit (17) · strengths: 5mg, 10mg, 15mg, 20mg, 2.5mg, 7.5mg · Rapid Dissolve Tab, Tab

CLOZAPINE

· 14 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg, 200mg, 25mg, 100mg ·

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: the manifestations of schizophrenia
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE LURASIDONE HYDROCHLORIDE · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4), General benefit (33), Listed, not a benefit (1) INDICATIONS AND CLINICAL USE Adults Schizophrenia Taro-Lurasidone (lurasidone hydrochloride tablets) is indicated for the management of the manifestations of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00065650.PDF; date not captured; DIN 02504499; fetched 2026-09-10 Product monograph ZUCLOPENTHIXOL DECANOATE · General benefit Indications CLOPIXOL (zuclopenthixol hydrochloride), CLOPIXOL ACUPHASE (zuclopenthixol acetate injection) and CLOPIXOL DEPOT (zuclopenthixol decanoate injection) are indicated for: • the management of the manifestations of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00085236.PDF; date 2026-06-30; DIN 02230406; fetched 2026-09-10 Product monograph ZUCLOPENTHIXOL DIHYDROCHLORIDE · General benefit Indications CLOPIXOL (zuclopenthixol hydrochloride), CLOPIXOL ACUPHASE (zuclopenthixol acetate injection) and CLOPIXOL DEPOT (zuclopenthixol decanoate injection) are indicated for: • the management of the manifestations of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00085236.PDF; date 2026-06-30; DIN 02230402; fetched 2026-09-10 Product monograph • the management of the manifestations of schizophrenia. CLOPIXOL (zuclopenthixol tablets as zuclopenthixol hydrochloride) may be used during initial treatment and for maintenance treatment. CLOPIXOL ACUPHASE (zuclopenthixol acetate injection) is intended for the initial treatment of acute psychotic episodes or exacerbation of psychosis associated with schizophrenia. CLOPIXOL DEPOT (zuclopenthixol decanoate injection) is intended for maintenance treatment. PM: https://pdf.hres.ca/dpd_pm/00085236.PDF; date 2026-06-30; DIN 02230402; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. INDICATIONS Schizophrenia SEROQUEL (quetiapine fumarate immediate-release) is indicated for: • the management of the manifestations of schizophrenia. The antipsychotic efficacy of SEROQUEL was established in short-term (6-week) controlled inpatient trials (see 14 CLINICAL TRIALS). The efficacy of SEROQUEL in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials of patients with manifestations of schizophrenia. Bipolar Disorder SEROQUEL is indicated as monotherapy for the: • acute management of manic episodes associated with bipolar disorder. • acute management of depressive episodes associated with bipolar I and bipolar II disorder. The efficacy of SEROQUEL in bipolar mania was established in two 12-week clinical trials of bipolar patients (see 14 CLINICAL TRIALS). The safety and effectiveness of SEROQUEL for long-term use, and for prophylactic use in bipolar mania has not been evaluated. The efficacy of SEROQUEL in bipolar depression was established in four 8-week clinical trials that included either bipolar I or bipolar II patients (see 14 CLINICAL TRIALS). 1.1 Pediatrics Pediatrics (< 18 years of age): Based on the … https://pdf.hres.ca/dpd_pm/00078929.PDF PM date: MAR 18, 2025 Source product: SEROQUEL; DIN 02236951; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Bio-Quetiapine · DIN 02447193 Shortage status: active shortage (reported 2024-05-08, last updated 2024-12-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02447193

Check this DIN again

Ach-Quetiapine Fumarate XR · DIN 02450860 Shortage status: active shortage (reported 2023-12-15, last updated 2024-01-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02450860

Check this DIN again

Apo-Quetiapine Fumarate · DIN 02501643 Shortage status: active shortage (reported not recorded, last updated 2024-09-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02501643

Check this DIN again